Naglaa Arafa

Naglaa Arafa

Auto-generated profile, based on publicly available information

Naglaa Arafa

Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Journal of Hepatology
Verified
Journal Article
Closed access
NANaglaa Arafa
Naglaa Arafa
MHMostafa El Hoseiny
Mostafa El Hoseiny
CRClaire Rekacewicz
Claire Rekacewicz
IBIman Bakr
Iman Bakr
SESherif El-Kafrawy
Sherif El-Kafrawy
AFArnaud Fontanet
Arnaud Fontanet

22 February 2010 in Liver International
Verified
Journal Article
Closed access
PDF file
AMAya Mostafa
Aya Mostafa
STSylvia M. Taylor
Sylvia M. Taylor
MEMai M. El-Daly
Mai M. El-Daly
MHMostafa El Hoseiny
Mostafa El Hoseiny
IBIman Bakr
Iman Bakr
MMMostafa K. Mohamed
Mostafa K. Mohamed

14 May 2008 in Gut
Verified
Journal Article
Closed access
PDF file
SPSabine Plancoulaine
Sabine Plancoulaine
MMM K Mohamed
M K Mohamed
NAN Arafa
N Arafa
IBI Bakr
I Bakr
CRC Rekacewicz
C Rekacewicz
AFA Fontanet
A Fontanet
Objective: Unsafe injections and transfusions used during treatments are considered to be responsible for many cases of transmission of hepatitis C virus (HCV) in developing countries, but cannot account for a substantial proportion of present infections. The aim of the present work was to investigate familial clustering of HCV infection in a population living in a highly endemic area. Design, setting and participants: A large seroepidemiological survey was conducted on 3994 subjects (age range, 2–88 years) from 475 familial clusters in an Egyptian rural area. Epidemiological methods appropriate for the analysis of correlated data were used to estimate risk factors and familial dependences for HCV infection. A phylogenetic analysis was conducted to investigate HCV strain similarities within and among families. Main outcome measures: HCV familial correlations adjusted for known risk factors, similarities between viral strains. Results: Overall HCV seroprevalence was 12.3%, increasing with age. After adjustment for relevant risk factors, highly significant intrafamilial resemblances in HCV seroprevalence were obtained between father–offspring (odds ratio (OR) = 3.4 (95% confidence interval (CI), 1.8 to 6.2)), mother–offspring (OR = 3.8 (95% CI, 2.5 to 5.8)), and sibling–sibling (OR = 9.3 (95% CI, 4.9 to 17.6)), while a weaker dependence between spouses (OR = 2.2 (95% CI, 1.3 to 3.7)) was observed. Phylogenetic analysis showed greater HCV strain similarity between family members than between unrelated subjects, indicating that correlations can be explained, in part, by familial sources of virus transmission. In addition, refined dissection of correlations between first-degree relatives supported the role of host genes predisposing to HCV infection. Conclusions: Current HCV infection in endemic countries has a strong familial component explained, at least partly, by specific modes of intrafamilial viral transmission and by genetic predisposition to infection.

1 September 2014 in The Lancet Global Health
Verified
Journal Article
Open access
RBRomulus Breban
Romulus Breban
NANaglaa Arafa
Naglaa Arafa
SLSandrine Leroy
Sandrine Leroy
AMAya Mostafa
Aya Mostafa
IBIman Bakr
Iman Bakr
AFArnaud Fontanet
Arnaud Fontanet
Most hepatitis C virus (HCV) transmission in Egypt is related to medical injections and procedures. To control the spread of HCV, the Egyptian Ministry of Health initiated awareness and education campaigns, strengthened infection control in health-care facilities, and subsidised anti-HCV treatment. We aimed to investigate the effect of these interventions on the spread of HCV by mathematical modelling. We developed a mathematical model of HCV transmission in Zawyat Razin, a typical rural community. Our model assumes that each individual has two distinct types of medical procedures: injections and more invasive medical procedures. To quantify the severity of the spread of HCV, we used the notion of the basic reproduction number R0, a standard threshold parameter signalling whether transmission of an infectious disease is self-sustained and maintains an epidemic. If R0 is greater than 1, HCV is self-sustained; if R0 is 1 or less, HCV transmission is not self-sustained. We investigated whether heterogeneity in the rate of injection or invasive medical procedures is the determinant factor for HCV transmission and whether most iatrogenic transmission is caused by a small group of individuals who receive health-care interventions frequently. We then assessed whether interventions targeted at this group could reduce the spread of HCV. The R0 of the spread of HCV without treatment was 3·54 (95% CI 1·28-6·18), suggesting a self-sustained spread. Furthermore, the present national treatment programme only decreased R0 from 3·54 to 3·03 (95% CI 1·10-5·25). Individuals with high rates of medical injections seem to be responsible for the spread of HCV in Egypt; the R0 of the spread of HCV without treatment would be 0·64 (95% CI 0·41-0·93) if everybody followed the average behaviour. The effect of treatment on HCV transmission is greatly enhanced if treatment is provided a mean of 2·5 years (95% CI 0·1-9·2) after chronic infection and with drug regimens with more than 80% efficacy. With these treatment parameters, preventive and curative interventions targeting individuals with high rates of medical injections might decrease R0 below 1 for treatment coverage lower than 5%. Targeting preventive and curative interventions to individuals with high rates of medical injections in Egypt would result in a greater reduction the spread of HCV than would untargeted allocation. Such an approach might prove beneficial in other resource-limited countries with health-care-driven epidemics. Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS 1211), ANR grant Labex Integrative Biology of Emerging Infectious Diseases.

17 July 2006 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
MMMostafa K. Mohamed
Mostafa K. Mohamed
IBIman Bakr
Iman Bakr
MEMostafa El‐Hoseiny
Mostafa El‐Hoseiny
NANaglaa Arafa
Naglaa Arafa
AHAbubakr Hassan
Abubakr Hassan
AFArnaud Fontanet
Arnaud Fontanet

1 March 2015 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
MFM.N. Farres
M.N. Farres
MRM. Refaat
M. Refaat
NMN.A. Melek
N.A. Melek
EAE.E. Ahmed
E.E. Ahmed
MSM.G. Shamseldine
M.G. Shamseldine
NAN.A. Arafa
N.A. Arafa
The pathogenesis of chronic urticaria is incompletely understood. There is growing interest in the role of the coagulation cascade in chronic urticaria. We aimed to assess the possible activation of the coagulation cascade in chronic spontaneous urticaria (CSU) in relation to disease severity and activity. This study was conducted on 30 patients with active CSU and 30 apparently healthy individuals as controls. Patients with acute urticaria, physical urticaria, or any form of urticaria other than spontaneous urticaria were excluded. Plasma levels of D-dimer and activated factor VII (FVIIa) were measured by ELISA at baseline for all recruited patients and controls. In addition, they were measured for CSU patients after complete disease remission. Plasma levels of D-dimer and FVIIa were significantly higher among patients with active CSU than among healthy controls. D-dimer levels were lowest among patients with grade 1 severity and highest among those with grade 4 severity. Factor VIIa levels did not differ significantly according to disease severity grades. After complete disease remission, there was a significant dramatic drop in levels of D-dimer and FVIIa among patients. We conclude that activation of the coagulation cascade occurs in CSU, and we demonstrate the novel finding that activated factor VII levels are significantly reduced after medical therapy, confirming the implication of the extrinsic pathway activation in CSU. Future controlled studies may investigate the role of anticoagulant therapy in refractory chronic urticaria.